HDAC-IN-30

• UNSPSC Description:

  HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC50=13.4 nM),HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM), HDAC6 (IC50=42.7 nM), HDAC8 (IC50=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy[1].

• Target Antigen:

  HDAC

• Type:

  Peptides

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hdac-in-30.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NO)CCCCCCNC(C1=C2C=CC=C1)=NN3C2=NC4=C(C=CC=C4)C3=O

• Molecular Weight:

  405.45

• References & Citations:

  [1]Liu Q, et al. Discovery of phthalazino [1, 2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway. Eur J Med Chem. 2022, 229:114058.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2756809-34-2